[Asia Economy Reporter Minji Lee] Tium Bio announced on the 28th that it has submitted a Phase 1/2 clinical trial plan to the US FDA to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the immuno-oncology drug TU2218 for patients with advanced cancer. The company stated, "TU2218 will also be submitted for additional clinical trials to the Korean Ministry of Food and Drug Safety as an MRCT study."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
